The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to ...

In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...